Association between the polymorphisms of 17beta-hydroxysteroid dehydrogenase type 5 or 6 and the risk of polycystic ovary syndrome: a systemic review and meta analysis

doi:10.3969/j.issn.1006-7795.2018.03.017

Abstract

Abstract: Objective To systematically evaluate the association between 17beta-hydroxysteroid dehydrogenase type 5 (HSD17B5) and type 6 (HSD17B6) single nucleotide polymorphisms (SNP) and the risk of polycystic ovary syndrome (PCOS).Methods A comprehensive electronic search about published reports on the association of HSD17B5 or HSD17B6 gene polymorphisms with PCOS in China and abroad,which was conducted in PubMed. The Cochrane Library, EMBASE (OVID), CNIK, CBM, WangFang Date and VIP database and the retrieval time was up to June 2017. Two reviewers independently screened the literature according to inclusion and exclusion criteria, extracted data and assessed the bias risk of the included studies. The pooled ORs were performed using the Revman 5.3 software.Results Eight case-control studies were included:5 were about HSD17B5 rs3763676 that including 899 cases and 751 controls and 4 were about HSD17B6 rs3763676 that including 1 065 cases and 942 controls. The results of genetic model meta analysis in 3 studies showed no significant association between HSD17B5 rs3763676 gene polymorphisms and risks of PCOS(G vs A:OR=1.21,95% CI:0.98-1.49,P=0.070;GG+AG vs AA:OR=1.26,95% CI:0.85-1.86,P=0.250;GG vs AG+AA:OR=1.35,95% CI:0.86-2.12,P=0.190;GG vs AA:OR=1.47,95% CI:0.91-2.38,P=0.110;AG vs AA:OR=1.19,95% CI:0.79-1.78,P=0.410). Approximately, no significant association between HSD17B6 rs3763676 gene polymorphisms and risks of PCOS (C vs T:OR=1.13,95% CI:0.96-1.32,P=0.140;CC+CT vs TT:OR=1.06,95% CI:0.88-1.27,P=0.570;CC vs CT+TT:OR=1.48,95% CI:0.95-2.29,P=0.080;CT vs TT:OR=0.99,95% CI:0.81-1.21,P=0.950) except for CC vs TT codominant model(CC vs TT:OR=1.46,95% CI:1.02-2.09,P=0.040), but the results should be interpreted with caution.Conclusion Both HSD17B5 rs3763676 and HSD17B6 rs898611 single nucleotide polymorphisms are no associated with the risks of PCOS, but the results should be interpreted with caution.

Key words: polycystic ovary syndrome, 17beta-hydroxysteroid dehydrogenase, polymorphism, Meta analysis

CLC Number:

R588.6

Li Qingchun, Xing Yingying, Jia Mengmeng, Cheng Xiaolin, Tian Xiaoyu. Association between the polymorphisms of 17beta-hydroxysteroid dehydrogenase type 5 or 6 and the risk of polycystic ovary syndrome: a systemic review and meta analysis[J]. Journal of Capital Medical University, 2018, 39(3): 404-412.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.03.017

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I3/404

References

[1] 沈铿, 马丁, 丰有吉,等. 妇产科学[M]. 3版.北京:人民卫生出版社, 2015:246-250.
[2] Yildiz B O, Bozdag G, Yapici Z, et al. Prevalence,phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria[J].Hum Reprod, 2012, 27(10):3067-3073.
[3] Balen A H, Morley L C, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome:an analysis of the evidence to support the development of global WHO guidance[J]. Hum Reprod Update, 2016, 22(6):687-708.
[4] 何晓彤, 孟祥雯, 张雪娇,等. 多囊卵巢综合征病因与发病机制的研究进展[J]. 中国妇幼保健, 2017, 32(7):1588-1591.
[5] Legro R S, Driscoll D, Strauss J F 3rd, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome[J]. Proc Natl Acad Sci USA, 1998, 95(25):14956-14960.
[6] Jonard S, Dewailly D. The follicular excess in polycystic ovaries,due to intra-ovarian hyperandrogenism,may be the main culprit for the follicular arrest[J]. Hum Reprod Update, 2004, 10(2):107-117.
[7] 曾宪涛, 刘慧, 陈曦,等. 分析系列之四:观察性研究的质量评价工具[J]. 中国循证心血管医学杂志, 2012, 4(4):297-299.
[8] Zeng X, Zhang Y, Kwong J S, et al. The methodological quality assessment tools for preclinical and clinical studies,systematic review and meta-analysis,and clinical practice guideline:a systematic review[J]. J Evid Based Med, 2015, 8(1):2-10.
[9] Qin K, Ehrmann DA, Cox N, et al. Identification of a functional polymorphism of the human type 517beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2006, 91(1):270-276.
[10] Jones M R, Italiano L, Wilson S G, et al. Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome[J]. Fertil Steril, 2006, 86(5):1438-1446.
[11] 柯纪定, 柯路, 王勇,等.多囊卵巢综合征与17β-HSD5基因多态性关系[J].中国公共卫生, 2007, 23(9):1119-1120.
[12] Goodarzi M O, Jones M R, Antoine H J, et al. Nonreplication of the type 517beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2008, 93(1):300-303.
[13] Marioli D J, Saltamavros A D, Vervita V, et al. Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism(-71AC HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome(PCOS)[J]. Fertil Steril, 2009, 92(2):648-652.
[14] Jones M R, Mathur R, Cui J, et al. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 617beta-hydroxysteroid dehydrogenase gene[J]. J Clin Endocrinol Metab, 2009, 94(12):5034-5038.
[15] Ke L, Che Y N, Cao Y X, et al. Polymorphisms of the HSD17B6 and HSD17B5 genes in Chinese women with polycystic ovary syndrome[J]. J Womens Health, 2010, 19(12):2227-2232.
[16] Ju R, Wu W, Fei J, et al. Association analysis between the polymorphisms of HSD17B5 and HSD17B6 and risk of polycystic ovary syndrome in Chinese population[J]. Eur J Endocrinol, 2015, 172(3):227-233.
[17] Wickenheisser J K, Nelson-Degrave V L, Mc Allister J M. Dysregulation of cytochrome P45017 alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome[J]. Clin Endocrinol Metab, 2005, 90(3):1720-1727.
[18] 苏文,许华敏,康继宏,等. 羟基类固醇脱氢酶的功能[J]. 生理科学进展, 2014, 45(1):27-31.
[19] Rosenfield R L, Barnes R B, Ehrmann D A. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism[J]. J Clin Endocrinol Metab,1994, 79(6):1686-1692.
[20] Nelson V L, Legro R S, Strauss J F 3rd, et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries[J]. Mol Endocrinol,1999, 13(6):946-957.
[21] Penning T M, Burczynski M E, Jez J M, et al. Structure-function aspects and inhibitor design of type 517-hydroxysteroid dehydrogenase (AKR1C3)[J]. Mol Cell Endocrino,2001, 1171(1-2):137-149.
[22] Biswas M G, Russell D W. Expression cloning and characterization of oxidative 17β-and 3α-dehydrogenases from rat and human prostate[J]. J Biol Chem, 1997, 272(25):15959-15966.
[23] Wood J, Nelson V L, Ho C, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis[J]. J Biol Chem, 2003, 278(29):26380-26390.
[24] Nelson V L,Qin K N, Rosenfield R L, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2001, 86(12):5925-5933.
[25] 智联腾,周钢桥,贺福初. 人类复杂疾病关联研究中群体分层的检出和校正[J]. 遗传, 2007, 29(1):3-7.
[26] Essah P A,Nestler J E,Carmina E. Difference in dyslipidemia between American and Italian women with polycystic ovary syndrome[J]. J Endocrinol Invest, 2008, 31(1):35-41.
[27] 张洪丽, 刘元宁, 张浩,等.精神分裂症易感基因的多位点关联性分析[J].吉林大学学报:工学版, 2008, 38(S2):205-212.
[28] 赵越, 阮祥燕,崔亚美,等.不同亚型的多囊卵巢综合征患者临床及实验室指标特征的研究[J].首都医科大学学报,2015,36(4):567-572.
[29] 赵彦楠,刘洪祥,霍佳宁,等.晚期糖基化终末产物在多囊卵巢综合征大鼠模型中的表达[J].中国医科大学学报,2017,46(5):388-391.